From Precision press release (my emphasis in bold):
" Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs in the future."; and
"For azer-cel, Precision is eligible to receive up to $198 million in additional milestone payments and double-digit royalties on net sales. For each additional research program selected by Imugene, Precision is eligible for up to $145 million in milestone payments and tiered royalties on net sales."
Thats about $1 billion AUD in milestone payments if Imugene exercise the additional 3 programs, plus royalties on all programs.
Ann: Investor Webinar featuring COO, Dr Glover & CMO, Dr Woodard, page-242
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.2¢ |
Change
-0.006(8.82%) |
Mkt cap ! $455.6M | |||
| Open | High | Low | Value | Volume |
| 6.9¢ | 7.1¢ | 6.2¢ | $3.774M | 58.30M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 3402693 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.3¢ | 610000 | 3 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |